Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Q32 Bio
Biotech
Q32 Bio sticks with bempikibart but lets go of staff
Despite the failure of an eczema trial, Q32 is staying faithful to bempikibart. But a number of the biotech’s “valued colleagues” won’t be so lucky.
James Waldron
Feb 11, 2025 4:47am
Q32's stock plunges in wake of anti-IL-7R antibody's eczema fail
Dec 11, 2024 8:25am
J&J's medtech chief out the door—Chutes & Ladders
Oct 27, 2023 9:30am
Maxwell Biosciences taps 3 leaders—Chutes & Ladders
Sep 23, 2022 9:30am
Lilly's longtime manufacturing chief to retire—Chutes & Ladders
Mar 12, 2021 10:13am
Ex-Intercept CMO Campagna lands at Q32
Mar 9, 2021 8:45am
